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Ring in the changes: Selective and specific inhibitors of Plasmodium falciparum tRNA 
synthetases represent promising therapeutic antimalarial avenues. Chemogenomic profiling of 
a focused library allowed the identification of a simplified cladosporin analogue, comprising 
an improved potency, a superior metabolic stability to that of its natural parent, and retaining 
its selectivity towards the human enzyme.  
Synthesis of a simplified analogue of the natural product cladosporin for #antimalarial 







Selective and specific inhibitors of Plasmodium falciparum lysyl-tRNA synthetase represent 
promising therapeutic antimalarial avenues. Cladosporin was identified as a potent 
P.^^falciparum lysyl-tRNA synthetase inhibitor, with an activity against parasite lysyl-tRNA 
synthetase >100-fold more potent than that of the activity registered against the human 
enzyme. Despite its compelling activity, cladosporin exhibits poor oral bioavailability; a 
critical requirement for antimalarial drugs. Thus, the quest to develop metabolically stable 
cladosporin-derived analogues, while retaining similar selectivity and potency to that of the 
natural compound, has begun. Chemogenomic profiling of a designed library allowed an 
entirely innovative structure--activity relationship study to be initiated; this shed light on 
structural evidence of a privileged scaffold with a unique activity against tRNA synthetases. 
Every year, malaria is responsible for over 500^^million cases requiring 
hospitalization. The rapid spread of antimalarial drug resistance limits the availability of 
armamentarium to treat these patients. Therefore, we are in urgent need of the next-generation 
drug that will shift the path towards increasing sustainability of treatment regimens and 
delaying the emergence and spread of drug resistance, as far as possible.[1--3] 
Cladosporin, a fungal secondary metabolite, was identified during the course of a 
screening campaign run against both Plasmodium falciparum blood- and liver-stage 
proliferation.[4] Intrigued by its potent activity, several research groups embarked on its 
biosynthesis and total synthesis to provide a path to advance it in the antimalarial drug 
pipeline.[5] Unpredictably, despite its enticing nanomolar antiparasitic activity, cladosporin 
regressed very quickly to a tool compound class that could no longer be progressed due to its 
weak metabolic stability and high clearance in vivo.[6] 
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In particular, for antimalarial drugs, oral bioavailability is critical because affected 
countries often lack the infrastructure for complex therapies. Cladosporin showed a very high 
clearance in both human and mouse models (subtype ER(human) 0.64^^CLint(µL^min<M-
>1^mg<M->1)=46.926; ER(mouse) 0.95^^CLint(µL^min<M->1^mg<M->1=425)).[6] To reveal 
potential liabilities that could impair further its development as a drug candidate, cladosporin 
was also incubated in vitro with mouse liver microsomes. Each sample was analyzed by 
means of capillary-HPLC/MS(n) and the proposed chemical structures were in accordance 
with accurate mass measurement of the corresponding protonated molecular ions. To our 
surprise, cladosporin was barely detectable. The only metabolic pathway that could be 
detected was the glucuronidation of cladosporin. More in-depth studies revealed three major 
fragmentations that helped to identify the structural Achilles’ heels responsible for fast 
clearance in both human and mouse. The weak points, including the three major 
fragmentations that were observed, are highlighted in Scheme^^1<schr1>. They serve in the 
elaboration of our lead optimization approach. 
The apparent structural simplicity of the cladosporin template motivated us to propose 
and synthesize a series of cladosporin-inspired analogues. The rationale for the design of our 
focused library was based on structural weaknesses revealed by our metabolic evaluation and 
in silico docking study based on cladosporin-lysyl-tRNA synthetase (KRS1) cocrystal 
structures published recently (Scheme^^1<xschr1>, Figure^^1<figr1> and the Supporting 
Information).[4] 
Indeed, the crystal structure can also be interrogated in stereochemical and structural 
terms. Cladosporin binds in the ATP-binding pocket of the lysyl-tRNA synthetase. The major 
interactions appear to be a hydrogen bond with Glu332 and the π/cation "cage" formed from 
adjacent aromatic and charged residues. The lactone ring interacts with the Arg559 main 
chain through structural water and must remain unchanged to retain the principal electrostatic 
interactions. Under these premises, we presumed that meaningful structure--activity 
relationship (SAR) studies should focus on the elucidation of the role of hydroxy groups, the 
tetrahydropyran frame, and carbon C4 of the isochromenone core (Figure^^2<figr2>). Any 
such structural editing, however, is difficult to achieve if one starts from the natural products 
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themselves; de novo synthesis seems to be much more appropriate to garner relevant insights. 
Because our group was previously involved in the synthesis of Agrimonolide,[5] we felt that 
we were in a strong position to venture into such an endeavor. Indeed, the variety of 
accumulated building blocks, starting from resorcinol to the m-methylaniline unit, allowed for 
the rapid generation of novel compounds with altered properties and unprecedented biological 
activities. 
Three main strategies were devised and executed in parallel to generate a focused 
library that was subsequently assessed for its activity and metabolic stability. Although not all 
steps were optimized for each individual analogue prepared during this campaign, the first 
route turned out to be efficient and reproducible in most cases. Starting from commercially 
available 3,5-methoxybromobenzene (1) and from tert-butyloxycarbonyl (N-Boc)-protected-
3-bromo-5-methylaniline (11), both C<C->Br bonds are activated under Stille coupling 
conditions in the presence of tetrakis(triphenylphosphine)palladium and LiCl to give the 
corresponding allyl derivatives 2 and 12 in 83 and 68^%, respectively. Next, compounds 2 
and 12 are cross-reacted with allylcyclopentane, allylcyclohexane, and 13[5] in the presence of 
the Grubbs II catalyst, and subjected to a Sharpless dihydroxylation with AD-mix-α to 
provide three new diol intermediates, 3, 4, and 14, as single enantiomers and in relatively 
good yield over two steps (29, 43, and 26^%, respectively).[7] After reaction with thiocarbonyl 
diimidazole in toluene at reflux, the corresponding thiocarbonates 5, 6, and 15 could be 
isolated. Further treatment with a mixture of Bu3SnH and azobisisobutyronitrile (AIBN),[8] 
allows for selective deoxygenation and the generation of the corresponding monoalcohols in a 
regioselective manner. Further treatment with trimethyl orthoformate under acidic conditions, 
followed by Jones oxidation, afforded the three corresponding lactones 7, 8, and 16.[9] Final 
deprotection in the presence of BBr3 yielded the first analogues, 9 and 10, in 60 and 73^% 
yield, respectively. Alternatively, lactone 16 was treated with a solution of trifluoroacetic acid 
(TFA) and subsequently hydrogenated to provide aniline analogue 17 in 46^% yield over two 
steps. Satisfyingly, this first generation of analogues allowed for the facile preparation of over 
30 analogues, in a 9-step procedure, with an overall yield of roughly 8^% 
(Scheme^^2<schr2>; see the Supporting Information for additional examples and respective 
data). 
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For our second approach, encouraged by the docking study and potential shape 
complementarity, we explored analogues containing a stereocontrolled tetrahydropyran core 
(Scheme^^3<schr3>). The synthesis of dihydroxyisocoumarins 25^a and 25^b commences 
with a similar strategy. Compound 1 is converted into 2-bromo-4,6-dimethoxybenzaldehyde 
under standard Vilsmeier--Haack conditions.[10] KMnO4 oxidation[11] and methyl iodide 
treatment in the presence of K2CO3 gives the desired methyl ester 18. Palladium-catalyzed 
Stille coupling with allytributylstannane affords allylic intermediate 19 (92^% yield), which is 
subjected to the Lemieux--Johnson oxidative cleavage,[12] to provide smoothly aldehyde 20. 
Subsequent enantioselective Brown allylation[13] delivers chiral homoallylic alcohol 21, which 
partially undergoes spontaneous intramolecular esterification with the neighboring ester 
functionality. Final cyclization of the remaining acyclic material is promoted by 
Amberlyst^^15 catalyst,[14] leading to allyl-modified isochromanone 22 in 60^% yield over 
two steps. This compound is finally exposed to a catalytic amount of Grubbs^^II complex 
(5^%) in benzene at 45^°C to perform a crosscoupling metathesis reaction with the 
homoallylic alcohol (S)-(<M+>)-hex-5-en-2-ol, leading to a remarkably clean formation of E-
olefin 23 in 64^% yield. At this stage, despite the fact that we were seemingly only two 
routine operations away from final lactone 25, we could not force the complete 
stereoselectivity of the ring-closure step. Moreover, given our interest in accessing both 
diastereoisomers, no particular effort was further dedicated to guide the stereoselectivity 
specifically for ring closure. Hence, the strategy continues with an iodine-mediated 
cyclization that allows the rapid generation of the C5-membered ring system. The iodo 
intermediate formed is engaged directly in a halogen--hydride exchange reaction by 
employing Bu3SnH/AIBN to yield a mixture of two diastereoisomers, 24^a and 24^b, which 
are highly inseparable. Only after proceeding to their separation through reversed-phase chiral 
HPLC were 24^a and 24^b isolated with 99^% diastereomeric excess (de).[15] Ultimate 
deprotection under Maier’s conditions (AlI3, TBAI, and phloroglucinol)[16] leads to lactones 
25^a and 25^b, which could be unambiguously characterized with a fully assigned 
configuration (see the Supporting Information). 
Our third strategy resembles a small pilot synthesis, on a simplified set of analogues. 
A representative case is outlined in Scheme^^4<schr4>. In fact, the presence of the 
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isocoumarin ring was known to be vital, but some structural modifications were allowed by 
the "π cage" formed with the aromatic residues. Inspired by previous findings from a set of 
compounds generated by biotransformation, we proposed to introduce a strategic unsaturation 
within the isocoumarin core, as illustrated by compound 28.[17a] 
As shown in Scheme^^4<xschr4>, our pivotal starting material, methyl 2-bromo-4,6-
dimethoxybenzoate (18) is subsequently engaged in a Sonogashira coupling reaction with 
prop-2-yn-1-ylcyclohexane (26) in the presence of a catalytic amount of copper iodide and 
trimethylamine, leading to alkynylaryl ester 27 in 80^% yield. FeCl3-mediated cyclization of 
27 selectively generated the expected six-membered ring product, which was subjected to 
BBr3 treatment, to afford analogue 28 ready for biological evaluation 
(Scheme^^4<xschr4>).[18] 
With all of these analogues in hand, we initiated a profiling campaign to assess their 
respective biological activity/selectivity for different tRNA synthetases/lysyl, threonine and 
phenylalanine, as well as their metabolic stability. Follow-up analysis, by means of the 
haploinsufficiency profiling (HIP) method and genetic mutational profiling, [19] confirmed that 
compounds 9, 10, and 28 were still on target, and the overall lysyl-tRNA binding mode was 
unchanged (see the Supporting Information).[20] This key assay allowed us not only to assess 
activity and selectivity in a cell-based fashion, but also to verify that the tested derivatives had 
the potential to penetrate even thick biological cell walls and membranes; an important 
requirement for potential anti-infectives. 
Critically, although presenting a relatively close structural similarity to that of 
cladosporin, compounds 9 and 10 (IC50, p.f.LysRS=0.3; 0.2^^µM) were found to be several-fold 
less potent and less selective than the parent compound cladosporin (Table^^1<tabr1>). 
Compounds 25^a and 25^b did not present any activity (IC50, p.f.LysRS>10^^µM). HIP analysis 
of compounds 17 and 29 (obtained from commercial sources) gave a most surprising outcome 
because their respective activity revealed that the observed cell-based activity was not elicited 
by inhibition of lysyl-tRNA synthetase, but rather threonyl- and phenylalanyl-tRNA 
synthetase, respectively (see the Supporting Information). 
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Finally, the metabolic stability was assessed for selected compounds with interesting 
biological activities. The results are reported in Table^^2<tabr2> as a measure of intrinsic 
clearance (CL int), half-life (t1/2), and ER in humans. As aligned with their low potency and 
selectivity, structural modifications conferred to compounds 9 and 10 did not address the 
metabolic stability aspect and were as weak as cladosporin. Astonishingly, the seemingly 
minor modifications proposed earlier payed off because compound 28 turned out to be 
significantly more potent than cladosporin itself, while conserving its selectivity and 
presenting a reasonable metabolic stability (Table^^2<xtabr2>). Notably, because the 
glucuronidated product of 28 could not be observed, we did not engage any further campaign 
to modify any of the hydroxy groups carried by the aromatic moiety of the molecule. 
In conclusion, we have successfully identified a simplified cladosporin analogue that 
presents not only improved potency and metabolic stability, compared with that of its natural 
parent, but retains selectivity towards the human enzyme. Gratifyingly, our screening 
campaign has led to the identification of two additional fungal active drugs that are selective 
inhibitors of threonyl- and phenylalanyl-tRNA synthetase, and thus, expanding the biological 
space modulated by this isocoumarin-derived scaffold. Additionally, as reported in the 
previous publication,[17a] an additional biotransformation-based approach resulted in the 
discovery of a set of active hydroxylated cladosporin analogues, which targeted specifically 
the lysyl-tRNA synthetase. This discovery represents a real breakthrough because it suggests 
that such a natural product derived structure could provide a privileged scaffold to inhibit 
synthetases beyond lysyl-tRNA synthetase. 
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Scheme^^1 Metabolic liabilities and proposed modifications for the cladosporin core 
structure. 
Scheme^^2 First-generation synthesis for the preparation of 9, 10, and 17. a)^^Vinyl-Bu3Sn, 
[Pd(PPh3)4] (2^^mol^%), Cs2CO3, DMF, 100^°C, 16^^h; 2: 83^%, 12: 68^%; 
b)^^allylcyclopentane or allylcyclohexane, Grubbs II cat. (10^^mol^%), CH2Cl2, reflux, 16--
30^^h; c)^^AD-mix-α, MeSO2NH2, tBuOH/H2O (1:1), 0^°C, 2--5^^days; 3: 29^%, 4: 43^%, 
14: 26^% (over two steps); d)^^thiocarbonyldiimidazole, 1,2-dichloroethane (DCE), reflux, 4-
-6^^h; 5: 36^%, 6: 78^%, 15: 50^%; e)^^Bu3SnH, AIBN, toluene, reflux, 4^^h; 
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f)^^CH(OMe)3, p-toluenesulfonic acid (p-TSA), CH2Cl2, RT, 2^^h; g)^^Jones reagent, 
acetone, 0^°C to RT, 1^^h; 7: 42^%, 8: 64^%, 16: 27^% (over three steps); h)^^BBr3, 
CH2Cl2, 0^°C to RT, 5^^days; 9: 60^%, 10: 73^%; i)^^TFA, CH2Cl2, RT, 16^^h; j)^^10^% 
Pd/C, H2, EtOAc, RT, 16^^h; 17: 46^% (over two steps). 
Scheme^^3 Second route proposed, leading to the isolation of 25^a and 25^b. a)^^POCl3, 
DMF, 100^°C, 4^^h, 91^%, b)^^KMnO4, H2O, 75^°C, 4^^h, 64^%, c)^^MeI, K2CO3, DMF, 
RT, 3^^h, 95^%. d)^^[Pd(PPh3)4], LiCl, allyltributylstanane, DMF, 100^°C, 24^^h, 92^%; 
e)^^OsO4, NaIO4, dioxane/water (3:1), RT, 5^^h, 62^%; f)^^(<M+>)-Ipc2B(allyl)borane 
((<M+>)-B-allyldiisopinocampheylborane), Et2O, <M->78^°C to RT, 2^^h; 
g)^^Amberlyst^^15, CH2Cl2, RT, 2^^days, 60^% (yield over two steps); h)^^(S)-(<M+>)-5-
hexen-2-ol, Grubbs II cat. (5^^mol^%), benzene, 45^°C, 6^^h, 64^%; i)^^I2, NaHCO3, 
toluene, <M->78^°C RT, 18^^h; then Bu3SnH, AIBN, benzene, 80^°C; 24^a: 21^%, 24^b: 
21^% (57^% yield over two steps and 42^% after chiral separation); j)^^Al, I2, 
tetrabutylammonium iodide (TBAI), phloroglucinol, benzene, 30^^min, 5^°C; 25^a: 58^%, 
25^b: 42^%. 
Scheme^^4 Third route for a simplified approach to cladosporin analogue 28. 
a)^^[Pd(PPh3)4], CuI, NEt3, DMF, 80^%; b)^^FeCl3, CH2Cl2, RT, 18^^h, 40^%; c)^^BBr3, 
CH2Cl2, RT, 8^^h, 55^%. 
Figure^^1 Pertinent part of the crystal structure of cladosporin/ KRS1: cladosporin binds in 
the adenosine triphosphate (ATP)-binding pocket of the lysyl-tRNA synthetase acylation 
domain. 
Figure^^2 A)^^Major interactions between cladosporin and KSR1. B)^^Structural 
modifications relative to the parent natural product cladosporin are colored; C4 of the 
isochromenone core is specifically annotated (4). 
Table^^1 <w=1>IC50 values for the inhibitory activity of the more potent cladosporin 
analogues in the two yeast species P.^^falciparum versus human. Values compared with the 
parent compound cladosporin. 
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Compound IC50 [µM] S.^^cerevisiae with HIP target hypothesis 
 human Lys.R.S. P.^^falciparum 
Lys.R.S. 
 
cladosporin 100 0.05 lysyl-tRNA synth. 
9 30 0.3 lysyl-tRNA synth. 
10 15 0.2 lysyl-tRNA synth. 
17 180 40 phenylalanyl-tRNA synth. 
25^a >100 >100 n.d.[a] 
25^b >100 >100 n.d.[a] 
28 10 0.02 lysyl-tRNA synth. 
<forr1> 40 40 threonyl-tRNA synth. 
[a]^^n.d.: not determined. 
Table^^2 <w=1>Metabolic stability assessment of the key synthetic analogues relative to 
the parent compound cladosporin. 
Compound Subtype t½ [min] Hepatic extraction [%] CL int [µL^min<M-
>1^mg<M->1] 
cladosporin human 269 12 6.9 
9 human 370 12 3.2 
10 human 405 12 3.4 
17 human 13 80 104 
 13 
28 human 14 79.5 101 
 
